Embla Genomics ApS: Financial statements 2022
CVR: 41685603
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Embla Genomics ApS (CVR 41685603) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -10,007 and a net result of DKK -8,431. Equity in the 2022 report amounted to DKK 60,472. The solvency ratio was 100%.
- Gross Profit
- DKK -10,007
- Profit/Loss
- DKK -8,431
- Equity
- DKK 60,472
- Total Assets
- DKK 60,472
- Employees
- 0
Official annual report
Keep an eye on Embla Genomics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Embla Genomics ApS has published its interim report for the period September 17, 2020 to December 31, 2021.
About Embla Genomics ApS
Embla Genomics ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company has been dissolved on 19 October 2026. The company was registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company has 2 employees (2021). In 2025, the company reported a gross profit of DKK 14,722 and a net result of DKK 7,398 compared with DKK -7,604 the year before. Equity in the 2025 report amounted to DKK 49,675.